AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
Stay current with the best on medical education
